Resveratrol

Verdict: Mostly hype Last reviewed: 2026-04-25 Triangulated against anchor: Resveratrol (this page is the canonical anchor for "Mostly hype")

TL;DR

Resveratrol is the textbook example of a longevity supplement with weak human evidence that achieved enormous commercial success. The early yeast and high-fat-diet mouse studies generated huge enthusiasm; the ITP tested it and found no lifespan extension; human trials show no meaningful biomarker effect at oral doses; the sirtuin-activation mechanism is contested; bioavailability is poor; and a 2025 meta-analysis showed resveratrol does not significantly raise human SIRT1 levels. Verdict: Mostly hype — the canonical anchor for that band.

What it is

A polyphenol stilbenoid found in grape skins, red wine, peanuts, and various berries. Available as supplement (powder, capsule). Typical doses: 100-1000 mg/day. Trans-resveratrol is the bioactive isomer.

Proposed mechanism

The original claim (Sinclair, Auwerx, et al.): resveratrol activates SIRT1, mimicking caloric restriction. Sirtuins were proposed as longevity-regulating deacetylases; resveratrol was framed as a "CR mimetic" via SIRT1 activation.

Confidence: Hypothetical. The SIRT1-activation claim has been substantially revised: 2025 meta-analyses show resveratrol supplementation does not significantly raise human SIRT1 activity. The original biochemical assays may have been artifact-prone. Some pleiotropic effects (anti-inflammatory, NAD+/NADH ratios) are plausible but small at achievable doses.

Evidence ladder

Invertebrate (T5)

Resveratrol extended lifespan in S. cerevisiae (Howitz 2003 Nature) and C. elegans / D. melanogaster in early studies. These findings were partially contested by replication failures (Bass 2007 found null results in flies and worms). The invertebrate evidence is genuinely mixed, not uniformly positive.

Mouse / rat (T4 — and the ITP failure is decisive)

Baur et al. 2006, Nature — resveratrol improved survival in mice on high-fat diet; framed as showing CR-like effects. Heavily cited.
Pearson 2008 — extended healthspan but not lifespan in normal-diet mice.
ITP testing: Resveratrol was tested by the ITP and failed to extend lifespan (Miller 2011, J Gerontol). Per methodology section 7, ITP failure on the gold-standard testing apparatus is decisive.
Effect size where positive: Healthspan markers improved in HFD models; no lifespan extension on standard diets.
Replication: Failed at the highest tier.

NHP (T4)

No major NHP lifespan or hard-endpoint data.

Human (T2 — biomarker only, mostly null)

Multiple small RCTs (typically 50-100 participants, weeks to months duration) on cardiometabolic markers, cognition, glucose handling. Results heterogeneous.
Sirtris / GSK clinical program — Sirtris was acquired by GSK for $720M based on resveratrol/SRT compounds; the program produced no successful clinical product and was discontinued. This is the strongest commercial-failure signal in the longevity field.
2025 GRADE-assessed meta-analysis (PubMed 40158656) — resveratrol supplementation does not significantly influence human SIRT1 levels in dose-response analysis. The mechanism the popular case rests on does not robustly engage in humans.
Bioavailability — oral resveratrol is heavily metabolized; tissue exposure is low. The "drink red wine for resveratrol" framing is essentially impossible at any reasonable wine volume.
No mortality data, no hard-endpoint RCT.

Confounds

Bioavailability undermines the entire dosing rationale; achievable plasma concentrations are far below those needed for the biochemical effects claimed in vitro.
Sirtris assays were partially artifactual — the fluorophore-coupled assays used in the original SIRT1-activation work were later shown to be susceptible to false positives.
High-fat-diet mouse studies show benefit relative to a uniquely unhealthy control diet, similar to the Wisconsin/NIA CR confound.
Publication bias has been documented in the polyphenol literature broadly.

Conflict of interest scan

Heavy commercial involvement: Sirtris (Sinclair-cofounded, GSK-acquired, discontinued), supplement industry, multiple "resveratrol longevity" books and products.
The 2025 critical meta-analysis was independent.
Net: substantial COI on the optimistic literature; the critical literature is academically led.

Human translation

Honest read: Resveratrol is the cleanest case study in the longevity field of a hypothesis being tested rigorously and failing. The yeast finding initiated a multi-billion-dollar industry; the mouse data was contested; the ITP failed it; the human clinical program collapsed; the 2025 mechanism analysis does not support the central claim.

This does not mean resveratrol is zero — small biological effects exist, anti-inflammatory signals at high doses are real. But the longevity claim, the "CR mimetic" claim, the "drink red wine for life" framing — all are not supported by current evidence.

Calibrated verdict

Mostly hype. This page is the canonical anchor for the Mostly hype band. Per methodology, Mostly hype is "popular intervention with only T0/T5 evidence, or T4 evidence that has failed replication at higher tiers." Resveratrol fits exactly: T4 evidence that failed at the ITP, popular intervention with extensive commercial support, mechanism contested at the most basic biochemical level.

Compared to NMN (Suggestive), resveratrol has been tested at the higher tier and failed (ITP), where NMN's closest cousin failed but NMN itself hasn't been formally ITP-tested. The trajectory difference is what separates the two anchors.

Compared to other polyphenols (quercetin, curcumin, EGCG), resveratrol has the most-tested null record. Other polyphenols may have similar reality but less rigorous testing to date.

Confidence interval on verdict

Will not move up. The ITP failure plus the SIRT1 mechanism failure are decisive.
Could move further "down" only if a clear safety signal emerged; none currently apparent.
Most likely 2-year trajectory: stable. Resveratrol's commercial market remains large but its scientific status is settled.

Open questions

Q: Is there a high-bioavailability resveratrol formulation (encapsulated, micronized) that achieves tissue levels closer to in vitro effective concentrations? Some commercial claims; data on hard endpoints essentially none.
Q: Are there subpopulations where resveratrol's anti-inflammatory effects are clinically meaningful (e.g., chronic inflammation in obesity)?
Q: Does pterostilbene (a methylated resveratrol analog with better bioavailability) repeat the resveratrol pattern, or does its distinct pharmacology produce different outcomes?

Sources

Produced under methodology locked 2026-04-24. Anchor for the Mostly hype band.